SCHEMBL832389

SCHEMBL832389

CCc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1CC1)n2Cc1ccc(C(N)=O)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.37
SCN9A Q15858 8/20 0.34
SCN5A Q14524 5/20 0.34
SCN2B O60939 2/20 0.34
SCN1B Q07699 2/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
SCN1A P35498 1/20 0.34
PTGER4 P35408 1/20 0.33
AGTR1 P30556 3/20 0.32
AGTR2 P50052 3/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831983 0.94 CYP2C8 (0.37) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL832356 0.91 CYP2C8 (0.40) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL831751 0.90 CYP2C8 (0.41) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL831353 0.88 CYP2C8 (0.36) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL10255265 0.87 CYP2C8 (0.40) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL831683 0.87 CYP2C8 (0.38) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL831963 0.87 CYP2C8 (0.40) CYP2C8SCN9AAGTR1AGTR2KMT2A
SCHEMBL831787 0.87 CYP2C8 (0.40) CYP2C8AGTR1AGTR2KMT2AMEN1
SCHEMBL862404 0.87 CYP2C8 (0.40) CYP2C8SCN9ASCN5ASCN2BSCN1B
SCHEMBL8861104 0.86 CYP2C8 (0.36) CYP2C8SCN9ASCN5ASCN2BSCN1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885SCN9A 3807/4885SCN5A 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.